TB Diagnostic Market By Type (Culture based diagnosis, Sputum test, Rapid Molecular Diagnosis, Others), By End-User (Hospitals, Diagnostic labs, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

TB Diagnostic Market

Tuberculosis (TB) is a bacterial infection caused by Mycobacterium tuberculosis that primarily affects the lungs and also other parts of the body. A persistent cough that lasts more than three weeks is the most common symptom of tuberculosis. The BCG vaccination is given to protect individuals from TB infections. Based on the organ affected, the common types of tuberculosis include pulmonary tuberculosis, brain tuberculosis, and skeletal tuberculosis.

A number of factors such as rise in the number of cigarette smokers, large number of patients suffering from HIV infection, undernutrition, diabetes, and alcohol use disorders contribute to the growing prevalence of TB. Various studies have shown that smoking damages the lungs, making smokers more susceptible to TB infection. In addition, this increase in the prevalence of TB helps boost the demand for TB diagnostics. Similarly, the increase in R&D activities for the diagnostic tests of tb with maximum effectiveness of the test product augments the growth of the market. Moreover, the research activities are funded by private organizations or the government authorities for the study of infectious disease diagnostics. Hence, the growth in the expenditure from these authorities boosts the research activities that help in the increased use of TB diagnostic thereby driving the growth of the market

Furthermore, acquisition, new product approval and product launch in market drives the growth of market For instance, in January 2023, Viatris Inc., a global healthcare company, announced its complete acquisition of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division. In addition, a rise in awareness about the effectiveness of TB diagnostic, surge in incidence of dry eye syndrome, increase in availability & affordability of healthcare treatment and rise in number of hospital admissions contributes to the growth of mMoreover, an increase in the research pipeline among diagnostic research organizations and rise in awareness about early tuberculosis screening help in the growth of the market. Furthermore, increase in number of product approval and product launch foster the expansion of the market. For instance, in February 2022, QIAGEN N.V., a leading diagnostic company, announced that its QuantiFERON-TB Gold Plus (QFT-Plus), the fourth generation of the modern gold standard for TB detection, received Chinese NMPA approval as test for active tuberculosis detection.

Moreover, an increase in the research pipeline among diagnostic research organizations and rise in awareness about early tuberculosis screening help in the growth of the market. Furthermore, increase in number of product approval and product launch foster the expansion of the market. For instance, in February 2022, QIAGEN N.V., a leading diagnostic company, announced that its QuantiFERON-TB Gold Plus (QFT-Plus), the fourth generation of the modern gold standard for TB detection, received Chinese NMPA approval as test for active tuberculosis detection. The market also offers growth opportunities to the key players in the market. The target population is in tremendous need of cost-effective services in regions like Europe and Asia-Pacific. Hence, challenges to cater the unmet needs of the target population provide growth opportunities. Online medical services have gained high traction in the last 4 years. As a result, engaged stakeholders in the industry have partnered with existing delivery services organizations.

The TB diagnostic market is segmented into drug, dosage form, distribution channel, and region. On the The TB diagnostic market is segmented on the basis of type, end user, and region. On the basis of type, the market is categorized into culture-based diagnosis, sputum smear test, rapid molecular diagnosis, and others. On the basis of end user, the market is classified into hospitals, diagnostic labs, and others. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The key players profiled in the Abbott Laboratories, Becton Dickinson and Company, Biomerieux SA, Molbio Diagnostics, Bio-Rad Laboratories, Danaher Corporation, F. Hoffmon La-Roche, Hologic Inc., Qiagen Inc and ThermoFisher Scientific. The players in the market have been actively engaged in the adoption of various strategies such as acquisition, product launch, and partnership to remain competitive and gain an advantage over the competitors in the market

                                                                                                                                        

Key Market Insights (Updated)

On the basis of Type, the rapid molecular diagnosis segment was the major share contributor in 2022.

By end user, the diagnostic labs segment dominated the market in 2022, and the ointments segment is expected to grow at the fastest CAGR during the forecast period.

Region wise, North America garnered the largest revenue share in 2022, however, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Overview

The TB Diagnostic Market was valued for $2,066.70 million in 2022 and is estimated to reach $3,102.20 million by 2032, exhibiting a CAGR of 4.1% from 2023 to 2032.

Tuberculosis (TB) is a bacterial infection caused by mycobacterium tuberculosis that primarily affects the lungs. It is a bacterial infection spread through inhaling tiny droplets from the coughs or sneezes of an infected person. TB is mainly diagnosed with the TB skin test (TST) and TB blood tests.

The growth of the TB diagnostic market is driven by an increase in the number of R&D activities, the surge in expenditure on product development by the government & private organizations, increase in the technological advancements of the diagnostics test’s products, and an upsurge in the number of hospital visits of the patients for TB screening. Furthermore, the increase in the prevalence of Tb infection drives the growth of the market. For instance, according to the World Health Organization (WHO), in 2021, an estimated 10.6 million people fell ill with tuberculosis (TB) worldwide.

Moreover, an increase in the research pipeline among diagnostic research organizations and rise in awareness about early tuberculosis screening help in the growth of the market. Furthermore, increase in number of product approval and product launch foster the expansion of the market. For instance, in February 2022, QIAGEN N.V., a leading diagnostic company, announced that its QuantiFERON-TB Gold Plus (QFT-Plus), the fourth generation of the modern gold standard for TB detection, received Chinese NMPA approval as test for active tuberculosis detection.

However, BCG vaccination, inaccurate pap smear testing, and the availability of other types of screening for TB are expected to hinder the growth of the market.

The TB diagnostic market is segmented on the basis of type, end user, and region. On the basis of type, the market is categorized into culture-based diagnosis, sputum smear test, rapid molecular diagnosis, and others. On the basis of end user, the market is classified into hospitals, diagnostic labs, and others. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major companies profiled in the report include Abbott Laboratories, Becton Dickinson and Company, Biomerieux SA, Molbio Diagnostics, Bio-Rad Laboratories, Danaher Corporation, F. Hoffmon La-Roche, Hologic Inc., Qiagen Inc and ThermoFisher Scientific.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the tb diagnostic market analysis from 2022 to 2032 to identify the prevailing tb diagnostic market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the tb diagnostic market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global tb diagnostic market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

● Quarterly Update and* (only available with a corporate license, on listed price)

● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

● Free Upcoming Version on the Purchase of Five and Enterprise User License.

● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

● Free data Pack on the Five and Enterprise User License. (Excel version of the report)

● Free Updated report if the report is 6-12 months old or older.

● 24-hour priority response*

● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

○ Qiagen NV

Scope of TB Diagnostic Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Moderate bargaining power of suppliers

3.3.2. Moderate threat of new entrants

3.3.3. Moderate threat of substitutes

3.3.4. Moderate intensity of rivalry

3.3.5. Moderate bargaining power of buyers

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Increase in the prevalence of tuberculosis

3.4.1.2. Rise in healthcare expenditure and improvements in healthcare facilities

3.4.1.3. Growth in initiatives from government organizations for tuberculosis awareness

3.4.2. Restraints

3.4.2.1. Lack of awareness about TB

3.4.3. Opportunities

3.4.3.1. High growth potential in developing economies

4.1. Overview

4.1.1. Market size and forecast

4.2. Culture based diagnosis

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Sputum test

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.4. Rapid Molecular Diagnosis

4.4.1. Key market trends, growth factors and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market share analysis by country

4.5. Others

4.5.1. Key market trends, growth factors and opportunities

4.5.2. Market size and forecast, by region

4.5.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Hospitals

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Diagnostic labs

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

5.4. Others

5.4.1. Key market trends, growth factors and opportunities

5.4.2. Market size and forecast, by region

5.4.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast By Region

6.2. North America

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by Type

6.2.3. Market size and forecast, by End-User

6.2.4. Market size and forecast, by country

6.2.4.1. U.S.

6.2.4.1.1. Market size and forecast, by Type

6.2.4.1.2. Market size and forecast, by End-User

6.2.4.2. Canada

6.2.4.2.1. Market size and forecast, by Type

6.2.4.2.2. Market size and forecast, by End-User

6.2.4.3. Mexico

6.2.4.3.1. Market size and forecast, by Type

6.2.4.3.2. Market size and forecast, by End-User

6.3. Europe

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by Type

6.3.3. Market size and forecast, by End-User

6.3.4. Market size and forecast, by country

6.3.4.1. Germany

6.3.4.1.1. Market size and forecast, by Type

6.3.4.1.2. Market size and forecast, by End-User

6.3.4.2. France

6.3.4.2.1. Market size and forecast, by Type

6.3.4.2.2. Market size and forecast, by End-User

6.3.4.3. UK

6.3.4.3.1. Market size and forecast, by Type

6.3.4.3.2. Market size and forecast, by End-User

6.3.4.4. Italy

6.3.4.4.1. Market size and forecast, by Type

6.3.4.4.2. Market size and forecast, by End-User

6.3.4.5. Spain

6.3.4.5.1. Market size and forecast, by Type

6.3.4.5.2. Market size and forecast, by End-User

6.3.4.6. Rest of Europe

6.3.4.6.1. Market size and forecast, by Type

6.3.4.6.2. Market size and forecast, by End-User

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by Type

6.4.3. Market size and forecast, by End-User

6.4.4. Market size and forecast, by country

6.4.4.1. China

6.4.4.1.1. Market size and forecast, by Type

6.4.4.1.2. Market size and forecast, by End-User

6.4.4.2. Japan

6.4.4.2.1. Market size and forecast, by Type

6.4.4.2.2. Market size and forecast, by End-User

6.4.4.3. India

6.4.4.3.1. Market size and forecast, by Type

6.4.4.3.2. Market size and forecast, by End-User

6.4.4.4. Australia

6.4.4.4.1. Market size and forecast, by Type

6.4.4.4.2. Market size and forecast, by End-User

6.4.4.5. South Korea

6.4.4.5.1. Market size and forecast, by Type

6.4.4.5.2. Market size and forecast, by End-User

6.4.4.6. Rest of Asia-Pacific

6.4.4.6.1. Market size and forecast, by Type

6.4.4.6.2. Market size and forecast, by End-User

6.5. LAMEA

6.5.1. Key market trends, growth factors and opportunities

6.5.2. Market size and forecast, by Type

6.5.3. Market size and forecast, by End-User

6.5.4. Market size and forecast, by country

6.5.4.1. Brazil

6.5.4.1.1. Market size and forecast, by Type

6.5.4.1.2. Market size and forecast, by End-User

6.5.4.2. Saudi Arabia

6.5.4.2.1. Market size and forecast, by Type

6.5.4.2.2. Market size and forecast, by End-User

6.5.4.3. South Africa

6.5.4.3.1. Market size and forecast, by Type

6.5.4.3.2. Market size and forecast, by End-User

6.5.4.4. Rest of LAMEA

6.5.4.4.1. Market size and forecast, by Type

6.5.4.4.2. Market size and forecast, by End-User

7.1. Introduction

7.2. Top winning strategies

7.3. Product Mapping of Top 10 Player

7.4. Competitive Dashboard

7.5. Competitive Heatmap

7.6. Top player positioning, 2022

8.1. Abbott Laboratories

8.1.1. Company overview

8.1.2. Key Executives

8.1.3. Company snapshot

8.1.4. Operating business segments

8.1.5. Product portfolio

8.1.6. Business performance

8.2. Becton Dickinson & Company

8.2.1. Company overview

8.2.2. Key Executives

8.2.3. Company snapshot

8.2.4. Operating business segments

8.2.5. Product portfolio

8.2.6. Business performance

8.3. Molbio Diagnostics Pvt. Ltd.

8.3.1. Company overview

8.3.2. Key Executives

8.3.3. Company snapshot

8.3.4. Operating business segments

8.3.5. Product portfolio

8.4. Bio-Rad Laboratories, Inc.

8.4.1. Company overview

8.4.2. Key Executives

8.4.3. Company snapshot

8.4.4. Operating business segments

8.4.5. Product portfolio

8.4.6. Business performance

8.5. Danaher Corporation

8.5.1. Company overview

8.5.2. Key Executives

8.5.3. Company snapshot

8.5.4. Operating business segments

8.5.5. Product portfolio

8.5.6. Business performance

8.6. Hologic Inc.

8.6.1. Company overview

8.6.2. Key Executives

8.6.3. Company snapshot

8.6.4. Operating business segments

8.6.5. Product portfolio

8.6.6. Business performance

8.7. Qiagen NV.

8.7.1. Company overview

8.7.2. Key Executives

8.7.3. Company snapshot

8.7.4. Operating business segments

8.7.5. Product portfolio

8.7.6. Business performance

8.8. Thermo Fisher Scientific Inc.

8.8.1. Company overview

8.8.2. Key Executives

8.8.3. Company snapshot

8.8.4. Operating business segments

8.8.5. Product portfolio

8.8.6. Business performance

8.9. bioMerieux SA

8.9.1. Company overview

8.9.2. Key Executives

8.9.3. Company snapshot

8.9.4. Operating business segments

8.9.5. Product portfolio

8.9.6. Business performance

8.10. F. Hoffmann-La Roche Ltd.

8.10.1. Company overview

8.10.2. Key Executives

8.10.3. Company snapshot

8.10.4. Operating business segments

8.10.5. Product portfolio

8.10.6. Business performanc

LIST OF TABLES

TABLE 01. GLOBAL TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 02. TB DIAGNOSTIC MARKET FOR CULTURE BASED DIAGNOSIS, BY REGION, 2022-2032 ($MILLION)

TABLE 03. TB DIAGNOSTIC MARKET FOR SPUTUM TEST, BY REGION, 2022-2032 ($MILLION)

TABLE 04. TB DIAGNOSTIC MARKET FOR RAPID MOLECULAR DIAGNOSIS, BY REGION, 2022-2032 ($MILLION)

TABLE 05. TB DIAGNOSTIC MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 06. GLOBAL TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)

TABLE 07. TB DIAGNOSTIC MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)

TABLE 08. TB DIAGNOSTIC MARKET FOR DIAGNOSTIC LABS, BY REGION, 2022-2032 ($MILLION)

TABLE 09. TB DIAGNOSTIC MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 10. TB DIAGNOSTIC MARKET, BY REGION, 2022-2032 ($MILLION)

TABLE 11. NORTH AMERICA TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 12. NORTH AMERICA TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)

TABLE 13. NORTH AMERICA TB DIAGNOSTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 14. U.S. TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 15. U.S. TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)

TABLE 16. CANADA TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 17. CANADA TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)

TABLE 18. MEXICO TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 19. MEXICO TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)

TABLE 20. EUROPE TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 21. EUROPE TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)

TABLE 22. EUROPE TB DIAGNOSTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 23. GERMANY TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 24. GERMANY TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)

TABLE 25. FRANCE TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 26. FRANCE TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)

TABLE 27. UK TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 28. UK TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)

TABLE 29. ITALY TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 30. ITALY TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)

TABLE 31. SPAIN TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 32. SPAIN TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)

TABLE 33. REST OF EUROPE TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 34. REST OF EUROPE TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)

TABLE 35. ASIA-PACIFIC TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 36. ASIA-PACIFIC TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)

TABLE 37. ASIA-PACIFIC TB DIAGNOSTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 38. CHINA TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 39. CHINA TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)

TABLE 40. JAPAN TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 41. JAPAN TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)

TABLE 42. INDIA TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 43. INDIA TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)

TABLE 44. AUSTRALIA TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 45. AUSTRALIA TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)

TABLE 46. SOUTH KOREA TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 47. SOUTH KOREA TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)

TABLE 48. REST OF ASIA-PACIFIC TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 49. REST OF ASIA-PACIFIC TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)

TABLE 50. LAMEA TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 51. LAMEA TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)

TABLE 52. LAMEA TB DIAGNOSTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 53. BRAZIL TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 54. BRAZIL TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)

TABLE 55. SAUDI ARABIA TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 56. SAUDI ARABIA TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)

TABLE 57. SOUTH AFRICA TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 58. SOUTH AFRICA TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)

TABLE 59. REST OF LAMEA TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 60. REST OF LAMEA TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)

TABLE 61. ABBOTT LABORATORIES: KEY EXECUTIVES

TABLE 62. ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 63. ABBOTT LABORATORIES: PRODUCT SEGMENTS

TABLE 64. ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 65. BECTON DICKINSON & COMPANY: KEY EXECUTIVES

TABLE 66. BECTON DICKINSON & COMPANY: COMPANY SNAPSHOT

TABLE 67. BECTON DICKINSON & COMPANY: PRODUCT SEGMENTS

TABLE 68. BECTON DICKINSON & COMPANY: PRODUCT PORTFOLIO

TABLE 69. MOLBIO DIAGNOSTICS PVT. LTD.: KEY EXECUTIVES

TABLE 70. MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY SNAPSHOT

TABLE 71. MOLBIO DIAGNOSTICS PVT. LTD.: PRODUCT SEGMENTS

TABLE 72. MOLBIO DIAGNOSTICS PVT. LTD.: PRODUCT PORTFOLIO

TABLE 73. BIO-RAD LABORATORIES, INC. : KEY EXECUTIVES

TABLE 74. BIO-RAD LABORATORIES, INC. : COMPANY SNAPSHOT

TABLE 75. BIO-RAD LABORATORIES, INC. : PRODUCT SEGMENTS

TABLE 76. BIO-RAD LABORATORIES, INC. : PRODUCT PORTFOLIO

TABLE 77. DANAHER CORPORATION: KEY EXECUTIVES

TABLE 78. DANAHER CORPORATION: COMPANY SNAPSHOT

TABLE 79. DANAHER CORPORATION: PRODUCT SEGMENTS

TABLE 80. DANAHER CORPORATION: PRODUCT PORTFOLIO

TABLE 81. HOLOGIC INC.: KEY EXECUTIVES

TABLE 82. HOLOGIC INC.: COMPANY SNAPSHOT

TABLE 83. HOLOGIC INC.: PRODUCT SEGMENTS

TABLE 84. HOLOGIC INC.: PRODUCT PORTFOLIO

TABLE 85. QIAGEN NV.: KEY EXECUTIVES

TABLE 86. QIAGEN NV.: COMPANY SNAPSHOT

TABLE 87. QIAGEN NV.: PRODUCT SEGMENTS

TABLE 88. QIAGEN NV.: PRODUCT PORTFOLIO

TABLE 89. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES

TABLE 90. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT

TABLE 91. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS

TABLE 92. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO

TABLE 93. BIOMERIEUX SA: KEY EXECUTIVES

TABLE 94. BIOMERIEUX SA: COMPANY SNAPSHOT

TABLE 95. BIOMERIEUX SA: PRODUCT SEGMENTS

TABLE 96. BIOMERIEUX SA: PRODUCT PORTFOLIO

TABLE 97. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES

TABLE 98. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT

TABLE 99. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS

TABLE 100. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO LIST OF FIGURES

FIGURE 01. TB DIAGNOSTIC MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF TB DIAGNOSTIC MARKET,2022-2032

FIGURE 03. TOP INVESTMENT POCKETS IN TB DIAGNOSTIC MARKET (2023-2032)

FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS

FIGURE 05. MODERATE THREAT OF NEW ENTRANTS

FIGURE 06. MODERATE THREAT OF SUBSTITUTES

FIGURE 07. MODERATE INTENSITY OF RIVALRY

FIGURE 08. MODERATE BARGAINING POWER OF BUYERS

FIGURE 09. GLOBAL TB DIAGNOSTIC MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 10. TB DIAGNOSTIC MARKET, BY TYPE, 2022 AND 2032(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF TB DIAGNOSTIC MARKET FOR CULTURE BASED DIAGNOSIS, BY COUNTRY 2022 AND 2032(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF TB DIAGNOSTIC MARKET FOR SPUTUM TEST, BY COUNTRY 2022 AND 2032(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF TB DIAGNOSTIC MARKET FOR RAPID MOLECULAR DIAGNOSIS, BY COUNTRY 2022 AND 2032(%)

FIGURE 14. COMPARATIVE SHARE ANALYSIS OF TB DIAGNOSTIC MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 15. TB DIAGNOSTIC MARKET, BY END-USER, 2022 AND 2032(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF TB DIAGNOSTIC MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF TB DIAGNOSTIC MARKET FOR DIAGNOSTIC LABS, BY COUNTRY 2022 AND 2032(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF TB DIAGNOSTIC MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 19. TB DIAGNOSTIC MARKET BY REGION, 2022 AND 2032(%)

FIGURE 20. U.S. TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)

FIGURE 21. CANADA TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)

FIGURE 22. MEXICO TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)

FIGURE 23. GERMANY TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)

FIGURE 24. FRANCE TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)

FIGURE 25. UK TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)

FIGURE 26. ITALY TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)

FIGURE 27. SPAIN TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)

FIGURE 28. REST OF EUROPE TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)

FIGURE 29. CHINA TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)

FIGURE 30. JAPAN TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)

FIGURE 31. INDIA TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)

FIGURE 32. AUSTRALIA TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)

FIGURE 33. SOUTH KOREA TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)

FIGURE 34. REST OF ASIA-PACIFIC TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)

FIGURE 35. BRAZIL TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)

FIGURE 36. SAUDI ARABIA TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)

FIGURE 37. SOUTH AFRICA TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)

FIGURE 38. REST OF LAMEA TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)

FIGURE 39. TOP WINNING STRATEGIES, BY YEAR

FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 42. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 43. COMPETITIVE DASHBOARD

FIGURE 44. COMPETITIVE HEATMAP: TB DIAGNOSTIC MARKET

FIGURE 45. TOP PLAYER POSITIONING, 2022

FIGURE 46. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)

FIGURE 47. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 48. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 49. BECTON DICKINSON & COMPANY: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 50. BECTON DICKINSON & COMPANY: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)

FIGURE 51. BECTON DICKINSON & COMPANY: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 52. BECTON DICKINSON & COMPANY: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 53. BIO-RAD LABORATORIES, INC. : NET SALES, 2020-2022 ($MILLION)

FIGURE 54. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 55. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY REGION, 2022 (%)

FIGURE 56. DANAHER CORPORATION: NET SALES, 2020-2022 ($MILLION)

FIGURE 57. DANAHER CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 58. DANAHER CORPORATION: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 59. HOLOGIC INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 60. HOLOGIC INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 61. HOLOGIC INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 62. QIAGEN NV.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 63. QIAGEN NV.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 64. QIAGEN NV.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 65. THERMO FISHER SCIENTIFIC, INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 66. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 67. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 68. BIOMERIEUX SA: NET SALES, 2020-2022 ($MILLION)

FIGURE 69. BIOMERIEUX SA: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 70. BIOMERIEUX SA: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 71. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2020-2022 ($MILLION)

FIGURE 72. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 73. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%